✨ Free AI Report
Minerva Neurosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Minerva Neurosciences, Inc.
Company Research

Minerva Neurosciences, Inc.: Business Overview, Financials & Competitive Analysis

Minerva Neurosciences, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-risk clinical-stage biotech with transformative upside if roluperidone Phase 3 succeeds, but facing regulatory hurdles and cash burn dynamics. The FDA confirmed that a new confirmatory clinical trial is required for roluperidone's NDA resubmission following a Complete Response Letter received in February 2024. While the company secured significant financing.

What is Minerva Neurosciences, Inc.'s industry? Minerva Neurosciences, Inc. (minervaneurosciences.com) operates in Biopharmaceutical / CNS Therapeutics. AskCyborg classifies Minerva Neurosciences, Inc. under Biopharmaceutical / CNS Therapeutics in its company registry.

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) dise...

4/ 10Mixed

Cyborg Score thesis

High-risk clinical-stage biotech with transformative upside if roluperidone Phase 3 succeeds, but facing regulatory hurdles and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / CNS Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Minerva Neurosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Minerva Neurosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Minerva Neurosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Minerva Neurosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Minerva Neurosciences, Inc. Overview

Pro stress-test →

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The company is developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease.

Strategic Profile

Pro stress-test →

Minerva raised up to $200 million in a private placement to fund a confirmatory Phase 3 trial of roluperidone, resubmission of its NDA, and preparation for a potential US commercial launch. The company co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder, with Janssen currently conducting Phase 3 trials.

Competitive Landscape

Pro stress-test →

Minerva competes in the CNS treatment space with larger pharmaceutical companies. Janssen Pharmaceutica partner on seltorexant co-development. Primary competition comes from established antipsychotics and other pipeline programs targeting schizophrenia negative symptoms and Parkinson's disease.

Industry Context

Minerva Neurosciences, Inc. operates in Biopharmaceutical / CNS Therapeutics.

Key facts

Founded: 2007 · Headquarters: Burlington, MA, US · Employees: 8 · Revenue: $0 · Market cap: $50M-$100M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Minerva Neurosciences, Inc..

  • Completed a private placement generating $80 million upfront with up to $200 million additional available if warrant milestones are met (October 2025).
  • FDA confirmed new confirmatory Phase 3 trial required after Complete Response Letter for roluperidone in February 2024.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Scheduled KOL event on roluperidone and negative symptoms in schizophrenia
  • October 2025Completed Series A private placement generating $80 million upfront
  • +1 moreTrack every material event for Minerva Neurosciences, Inc. as it happens. Explore monitoring →
Get alerted when Minerva Neurosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Antipsychotics (Various)Established schizophrenia treatments→SeltorexantCo-developed with Minerva for insomnia and depression→Levodopa and variantsStandard Parkinson's disease treatments→

Compare Minerva Neurosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Minerva Neurosciences, Inc. operates in Biopharmaceutical / CNS Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / CNS Therapeutics research →
NEW · MCP server

Ask your AI assistant about Minerva Neurosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Minerva Neurosciences, Inc. and its top competitor on Cyborg Score”
“What did Minerva Neurosciences, Inc. do this quarter?”
“Is Minerva Neurosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Minerva Neurosciences, Inc. do?+
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) dise...
What is Minerva Neurosciences, Inc.'s Cyborg Score?+
Minerva Neurosciences, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Minerva Neurosciences, Inc.'s main competitors?+
Named competitors include Antipsychotics (Various), Seltorexant, Levodopa and variants. The full competitive landscape is in the AskCyborg report.
How can I get the full Minerva Neurosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Minerva Neurosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Minerva Neurosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score